Jackson Laboratory Wins ARPA-H Funding for Rare CNS Diseases
BAR HARBOR, Maine, USA, July 9, 2026 The Jackson Laboratory (JAX), in collaboration with the Broad Institute and a...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
BAR HARBOR, Maine, USA, July 9, 2026 The Jackson Laboratory (JAX), in collaboration with the Broad Institute and a...
PHILADELPHIA, Pennsylvania, USA, July 9, 2026 GEMMA Biotherapeutics (GEMMABio) has been awarded funding from the Advanced Research Projects Agency...
CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...
NEW YORK, NY, June 11, 2026 Cellectis announced final Phase 1 results from the BALLI-01 clinical trial evaluating lasme-cel,...
SÖDERTÄLJE, Sweden, June 11, 2026 Anocca AB announced the successful dosing of the first patients in its VIDAR-1 clinical...
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
SOUTH SAN FRANCISCO, Calif., May 2026 Mission Bio announced new data demonstrating the power of its Targeted Single-Cell DNA+RNA...
